PYCR1-IN-1
Based on 2 publication(s) in Google Scholar
PYCR1-IN-1 (compound 4) is a pyrroline-5-carboxylate reductase 1 (PYCR1) inhibitor with an IC50 of 8.8 µM. PYCR1-IN-1 has anticancer effects.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.65%
- CAS No.: 709-85-3
- 화학식: C11H12BrN
- 분자량:238.13
-
보관:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Breast Cancer Compound Library
HY-L074
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
-
Alkyne Compound Library
HY-L258
Publications Citing Use of MedChemExpress (MCE) PYCR1-IN-1
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
IC50: 8.8 µM (PYCR1)[1]
PYCR1-IN-1 (0-100 μM, 24 h) decreases the proline level, inhibits the proliferation of human breast cancer cell SUM-159-PT and MDA-MB-231 without additionally supplement of proline (inhibition rate=30-40%)[1].
PYCR1-IN-1 inhibits pyrroline-5-carboxylate reductase (IC50=8.7 μM with the utilization of NADPH as electron donor), interfers with the proline/pyrroline-5-carboxylate cycle, inhibiting thereby the growth of cancer cell[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SUM-159-PT and MDA-MB-231
-
Concentration:10 μM
-
Incubation Time:1-5 days
-
Result:Inhibited the cell proliferation.
Chemical Information
-
CAS No. 709-85-3
-
Appearance Liquid (Density: 1.330±0.06 g/cm3)
-
분자량 238.13
-
화학식 C11H12BrN
-
Color Colorless to light yellow
-
SMILES
C#CCN(C)CC1=CC=C(Br)C=C1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Exp Mol Med
PYCR1 drives lung cancer progression through functional interactions with EGFR and TLR signaling pathways. [Abstract]2025 Nov;57(11):2559-2573. PMID: 41254241 -
J Transl Med
Glutamine metabolism reprogramming promotes bladder cancer progression via PYCR1: a multi-omics and functional validation study. [Abstract]2025 Nov 13;23(1):1277. PMID: 41233804
용액&용해도
DMSO : 100 mg/mL (419.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (272 KB)
-
SDS (615 KB)
- English - EN (615 KB)
- Français - FR (615 KB)
- Deutsch - DE (615 KB)
- Norwegian - NO (615 KB)
- Español - ES (615 KB)
- Swedish - SV (615 KB)
- Italian - IT (615 KB)
- Korean - KR (615 KB)
- Portuguese - PT (615 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kirsty Milne, et al. A fragment-like approach to PYCR1 inhibition. Bioorg Med Chem Lett. 2019 Sep 15;29(18):2626-2631. [Content Brief]
[2]. Forlani G, et al., Phenyl-substituted aminomethylene-bisphosphonates inhibit human P5C reductase and show antiproliferative activity against proline-hyperproducing tumour cells. J Enzyme Inhib Med Chem. 2021 Dec;36(1):1248-1257. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1994 mL | 20.9969 mL | 41.9939 mL | 104.9847 mL |
| 5 mM | 0.8399 mL | 4.1994 mL | 8.3988 mL | 20.9969 mL | |
| 10 mM | 0.4199 mL | 2.0997 mL | 4.1994 mL | 10.4985 mL | |
| 15 mM | 0.2800 mL | 1.3998 mL | 2.7996 mL | 6.9990 mL | |
| 20 mM | 0.2100 mL | 1.0498 mL | 2.0997 mL | 5.2492 mL | |
| 25 mM | 0.1680 mL | 0.8399 mL | 1.6798 mL | 4.1994 mL | |
| 30 mM | 0.1400 mL | 0.6999 mL | 1.3998 mL | 3.4995 mL | |
| 40 mM | 0.1050 mL | 0.5249 mL | 1.0498 mL | 2.6246 mL | |
| 50 mM | 0.0840 mL | 0.4199 mL | 0.8399 mL | 2.0997 mL | |
| 60 mM | 0.0700 mL | 0.3499 mL | 0.6999 mL | 1.7497 mL | |
| 80 mM | 0.0525 mL | 0.2625 mL | 0.5249 mL | 1.3123 mL | |
| 100 mM | 0.0420 mL | 0.2100 mL | 0.4199 mL | 1.0498 mL |
PYCR1-IN-1 Related Classifications
HY-126271 Related Classifications
Powered by Bioz